Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare brain tumor: drug trial targets regrowth

NCT ID NCT06970145

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety and effectiveness of anlotinib, a drug that blocks blood vessel growth, in 57 adults whose craniopharyngioma has come back after surgery. The main goal is to see if the drug shrinks the tumor. Researchers will also track how long the tumor stays controlled and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 57 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-75 years old, regardless of gender 2. recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data 3. predominantly cystic or solid recurrence of the tumor 4. measurable lesions (according to the RECIST criteria) 5. Karnofsky score ≥ 70, expected survival ≥ 3 months 6. laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control 7. signed informed consent and willing to participate in the study Exclusion Criteria: 1. Have a combination of other intracranial tumors or severe brain lesions 2. primary craniopharyngioma 3. have severe uncontrolled heart, lung, kidney, or liver disease 4. children, pregnant or breastfeeding women 5. prior treatment with the same investigational drug 6. active infections, including HIV, HBV, or HCV infections 7. patients who do not meet the contraindications to the medication 8. have a history of severe allergy to the investigational drug 9. have psychiatric illnesses or cognitive impairments and unable to complete follow-up visits or understand the purpose of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Craniopharyngiomas are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

craniopharyngioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Craniopharyngiomas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Southern Medical University, Nanfang Hospital, Department of Neurosurgery

    RECRUITING

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.